Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM1FDN8)

• Drug Name: Mizolastine Drug Info
• Synonyms: Mistalin; Mistamine; Mizolastina; Mizolastinum; Mizolen; Mizollen; Zolim; Zolistam; Zolistan; Allphar brand of mizolastine; Galderma brand of mizolastine; Mizolastine [INN]; Novag brand of mizolastine; Sanofi Synthelabo brand of mizolastine; Schwarz brand of mizolastine; MKC-431; Mizolastina [INN-Spanish]; Mizolastinum [INN-Latin]; Mizollen (TN); SL 85.0324; Mizolastine (JAN/INN); SL-85.0324; 2-((1-(1-(p-Fluorobenzyl)-2-benzimidazolyl)-4-piperidyl)methylamino)-4(3H)-pyrimidinone; 2-[[1-[1-[(4-fluorophenyl)methyl]benzimidazol-2-yl]piperidin-4-yl]-methylamino]-1H-pyrimidin-6-one
• Therapeutic Class: Antiallergic Agents
• Cross-matching ID:
  PubChem CID: 65906
  ChEBI ID: CHEMBL94454
  CAS Number: CAS 108612-45-9
  TTD Drug ID: D06MAJ
  VARIDT Drug ID: DR00777

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Melanogenesis	1.95	1.14e-2	74/101 (73.27%)	PLCB1;CALML3;PLCB3;...
Proximal tubule bicarbonate reclamation	1.94	5.71e-3	21/23 (91.3%)	CA2;SLC4A4;PCK1;...
Gastric acid secretion	1.86	1.52e-2	63/76 (82.89%)	MYLK;PLCB1;CA2;...
Phosphatidylinositol signaling system	1.84	2.28e-2	82/97 (84.54%)	PLCB1;CALML3;PIK3R3;...
Dopaminergic synapse	1.80	2.97e-2	115/132 (87.12%)	PLCB1;CALML3;PLCB3;...
Long-term potentiation	1.80	2.47e-2	61/67 (91.04%)	PLCB1;CALML3;PLCB3;...
Inositol phosphate metabolism	1.76	3.92e-2	66/73 (90.41%)	PLCB1;PLCB3;INPP5A;...
Glycolysis / Gluconeogenesis	1.76	3.43e-2	56/67 (83.58%)	ENO2;PCK1;ADH1B;...
Carbohydrate digestion and absorption	1.75	3.05e-2	37/47 (78.72%)	PLCB1;PIK3R3;PLCB3;...
Vascular smooth muscle contraction	1.75	2.85e-2	113/133 (84.96%)	MYLK;PLCB1;MYH11;...
ECM-receptor interaction	1.74	2.80e-2	80/88 (90.91%)	CD36;FN1;THBS1;...
Thyroid hormone signaling pathway	1.73	3.43e-2	112/121 (92.56%)	PLCB1;BMP4;NOTCH1;...
Progesterone-mediated oocyte maturation	1.72	3.51e-2	75/100 (75%)	CCNB2;PIK3R3;CDC25B;...
Phenylalanine metabolism	1.71	3.75e-2	14/17 (82.35%)	MAOA;MAOB;AOC3;...
Bladder cancer	-1.91	2.85e-2	40/41 (97.56%)	EGF;ERBB2;FGFR3;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF7	CVCL_0031	Homo sapiens	0.01uM - 10uM	6H, 24H	Hide ▲

Cervix

Cervical adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HeLa	CVCL_0030	Homo sapiens	0.01uM - 10uM	24H	Hide ▲

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Pancreas

Pancreatic carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
YAPC	CVCL_1791	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
PC-3	CVCL_0035	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	0.01uM - 10uM	24H	Show ▼